DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Williams syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWilliams syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for williams syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
histamine receptor H1 (HRH1) — HRH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hsmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8YN2 · 2.66 Å · ligand HISTAMINE (HSM). Experimental structure, not a prediction.
What the evidence adds up to
A 2020 set of consensus recommendations for paediatricians outlines general care for children with Williams syndrome diagnosed by chromosome 7 microdeletion, but it does not report any drug trial or treatment outcome. The recommendations explicitly state they do not replace individualised medical assessment.
A 2014 case report describes one 19-year-old woman with Williams syndrome who developed anger, aggression, and hair-pulling one week after an upper gastrointestinal endoscopy that used fentanyl, midazolam, and propofol. Her neuropsychiatric symptoms were treated with N-acetylcysteine. The authors report that the treatment was successful for this single patient, but no sample size, response rate, or controlled data are provided. No other patients are described.
A 2025 case report of a 7-year-old girl with Williams syndrome notes that she had ocular discomfort and hypermetropia alongside classic features such as distinct facial characteristics and developmental delays. No drug treatment or intervention is described in this report.
What is still missing: no randomised controlled trials exist for any drug in Williams syndrome. The only pharmacological report is a single unblinded case. No funding for a proper trial, no validated outcome measures for the neuropsychiatric symptoms, and no patient stratification by age or genetic deletion size have been established.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 2020 · 205 citations
Health Care Supervision for Children With Williams Syndrome
AbstractThis set of recommendations is designed to assist the pediatrician in caring for children with Williams syndrome (WS) who were diagnosed by using clinical features and with chromosome 7 microdeletion confirmed by fluorescence in situ hybridization, chromosome microarray, or multiplex ligation-dependent probe amplification. The recommendations in this report reflect review of the current literature, including previously peer-reviewed and published management suggestions for WS, as well as the consensus of physicians and psychologists with expertise in the care of individuals with WS. These general recommendations for the syndrome do not replace individualized medical assessment and treatment.
N-Acetylcysteine for Neuropsychiatric Symptoms in a Woman With Williams Syndrome
AbstractWilliams syndrome is a relatively rare genetic disorder caused by the hemizygous microdeletion of a region in chromosome 7q11.23. Individuals with Williams syndrome typically present with a highly social, overfriendly, and empathic personality. Comorbid medical and neuropsychiatric disorders are common. Reports of effective pharmacological treatment of associated neuropsychiatric disorders are limited. The authors describe the successful treatment of interfering anger, aggression, and hair-pulling with N-acetylcysteine in a 19-year-old woman with Williams syndrome. The neuropsychiatric symptoms emerged 1 week following an upper gastrointestinal endoscopy, for which fentanyl, midazolam, and propofol were used as anesthetics. The patient's treatment course and hypothesized mechanisms underlying the clinical presentation and symptom resolution are described.
Latin American Journal of Ophthalmology · 2025 · 0 citations · open access
Williams syndrome with ocular discomfort and hypermetropia: Unveiling the multifaceted clinical presentation
AbstractWilliams syndrome is a neurodevelopmental genetic disorder caused by a deletion of genes on chromosome 7. It is characterized by a distinctive combination of physical, cognitive, and behavioral features as well as cardiovascular abnormalities such as supravalvular aortic stenosis. In this case, the 7-year-old female patient presented with classic features of Williams syndrome, including distinct facial characteristics, developmental delays, and reported ocular discomfort.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
